Drug Trial Radar · NCT01970371
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Last checked: Nov 20, 2026Latest source record: Oct 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Sep 16, 2014
Primary completion
Aug 18, 2016
Study completion Sep 15, 2016
Sponsor
- Lead sponsor
- Achaogen, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Department of Health and Human Services
- First posted
- Oct 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in the treatment of patients with bloodstream infection (BSI), hospital acquired bacterial pneumonia (HABP), or ventilator-associated bacterial pneumonia (VABP) due to CRE. An additional cohort of patients with BSI, HABP, VABP, complicated urinary tract infection (cUTI), or acute pyelonephritis (AP) due to CRE, not eligible for inclusion in the other cohort, were enrolled into a single arm (Cohort 2) and treated with plazomicin-based therapy. Therapeutic drug management (TDM) was used to help ensure that plazomicin exposures lie within an acceptable range of the target mean steady-state area under the curve (AUC).
Conditions
- Bloodstream Infections (BSI) Due to CRE
- Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
- Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE
- Complicated Urinary Tract Infection (cUTI) Due to CRE
- Acute Pyelonephritis (AP) Due to CRE
Interventions
plazomicinDrug
colistinDrug
meropenemDrug
tigecyclineDrug
antibiotic of Investigator's choiceDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat (mMITT) Population in Cohort 1Time frame: Up to Day 28 for ACM, up to 7 Days for SDRCs in all patients, on or after Day 5 for BSI patients only.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.